Christopher P Leamon
Christopher P Leamon
Endocyte Inc
Verified email at endocyte.com
Title
Cited by
Cited by
Year
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
N Parker, MJ Turk, E Westrick, JD Lewis, PS Low, CP Leamon
Analytical biochemistry 338 (2), 284-293, 2005
11552005
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.
CP Leamon, PS Low
Proceedings of the National Academy of Sciences 88 (13), 5572-5576, 1991
7581991
Folate-targeted chemotherapy
CP Leamon, JA Reddy
Advanced drug delivery reviews 56 (8), 1127-1141, 2004
7232004
Folate-mediated targeting: from diagnostics to drug and gene delivery
CP Leamon, PS Low
Drug discovery today 6 (1), 44-51, 2001
5032001
Synthesis and Biological Evaluation of EC20:  A New Folate-Derived, 99mTc-Based Radiopharmaceutical
CP Leamon, MA Parker, IR Vlahov, LC Xu, JA Reddy, M Vetzel, ...
Bioconjugate chemistry 13 (6), 1200-1210, 2002
2982002
Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential
Y Lu, E Sega, CP Leamon, PS Low
Advanced drug delivery reviews 56 (8), 1161-1176, 2004
2952004
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery
CM Paulos, JA Reddy, CP Leamon, MJ Turk, PS Low
Molecular pharmacology 66 (6), 1406-1414, 2004
2762004
Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells
JJ Turek, CP Leamon, PS Low
Journal of cell science 106 (1), 423-430, 1993
2451993
Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo
CP Leamon, SR Cooper, GE Hardee
Bioconjugate chemistry 14 (4), 738-747, 2003
2422003
Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain.
CP Leamon, I Pastan, PS Low
Journal of Biological Chemistry 268 (33), 24847-24854, 1993
2401993
The folate receptor as a rational therapeutic target for personalized cancer treatment
YG Assaraf, CP Leamon, JA Reddy
Drug Resistance Updates 17 (4-6), 89-95, 2014
2382014
Engineering folate–drug conjugates to target cancer: from chemistry to clinic
IR Vlahov, CP Leamon
Bioconjugate chemistry 23 (7), 1357-1369, 2012
2292012
Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors
JA Reddy, C Abburi, H Hofland, SJ Howard, I Vlahov, P Wils, CP Leamon
Gene therapy 9 (22), 1542-1550, 2002
2162002
Cytotoxicity of momordin-folate conjugates in cultured human cells.
CP Leamon, PS Low
Journal of Biological Chemistry 267 (35), 24966-24971, 1992
2111992
Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate
JA Reddy, R Dorton, E Westrick, A Dawson, T Smith, LC Xu, M Vetzel, ...
Cancer research 67 (9), 4434-4442, 2007
2002007
Targeting therapeutic and imaging agents to folate receptor positive tumors
JA Reddy, VM Allagadda, CP Leamon
Current pharmaceutical biotechnology 6 (2), 131-150, 2005
1962005
Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells
CP Leamon, PS Low
Biochemical Journal 291 (3), 855-860, 1993
1851993
Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide
IR Vlahov, HKR Santhapuram, PJ Kleindl, SJ Howard, KM Stanford, ...
Bioorganic & medicinal chemistry letters 16 (19), 5093-5096, 2006
1782006
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum …
RW Naumann, RL Coleman, RA Burger, EA Sausville, E Kutarska, ...
J Clin Oncol 31 (35), 4400-4406, 2013
1692013
Folate-targeted gene transfer in vivo
HEJ Hofland, C Masson, S Iginla, I Osetinsky, JA Reddy, CP Leamon, ...
Molecular Therapy 5 (6), 739-744, 2002
1642002
The system can't perform the operation now. Try again later.
Articles 1–20